Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Atheronova, Inc. (OTC: AHROQ).

Full DD Report for AHROQ

You must become a subscriber to view this report.

About Atheronova, Inc. (OTC: AHROQ)

Logo for Atheronova, Inc. (OTC: AHROQ)

AtheroNova Inc. is a clinical stage biotech company focused on discovery, research, development and licensing of novel compounds to reduce or regress atherosclerotic plaque deposits. Atherosclerotic plaque, which progressively narrows and blocks arteries, is the main underlying pathology of cardiovascular disease and the leading killer in industrialized nations worldwide. The Company s focus on compounds to reduce or eliminate atherosclerotic plaque deposits addresses the most lucrative segments of the multi billion dollar prescription drug market: cardiovascular disease and stroke prevention. Key Investment Considerations Billion market potential Strong IP protection Identifiable milestones Potentially lower risk of safety or efficacy problems than is typical in drug development Strong management team with successful track record Capital structure


Contact Information



Current Management

  • Thomas Gardner / CEO
  • Mark Selawski / CFO, Secretary
  • Louis Wharton, Esq. / Counsel
  • Thomas Gardner / Chairman
  • Paul DiPerna /
  • Fred Knoll /
  • Alexander Polinsky /
  • Boris Ratiner /
  • Johan M. Spoor /
  • Thijs Spoor /

Current Share Structure

  • Market Cap: $48,450 - 03/16/2018
  • Authorized: 100,000,000 - 11/05/2014
  • Issue and Outstanding: 8,809,139 - 11/05/2014
  • Float: 5,417,704 - 11/05/2014


Recent Filings from (OTC: AHROQ)

Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 12 2016
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 08 2016



Daily Technical Chart for (OTC: AHROQ)

Daily Technical Chart for (OTC: AHROQ)

Stay tuned for daily updates and more on (OTC: AHROQ)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: AHROQ)

Do your DD and if you choose, be ready to go!


The Research: All source information contained in this email is from the public sources mentioned below.



Thank you

OTC Report



Disclaimer: OTC Report publishes reports providing information on selected companies. OTC Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. OTC Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AHROQ is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. OTC Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. OTC Report does not own any shares of AHROQ and does not buy, sell, or trade any shares of AHROQ. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by OTC Report. All rights reserved. Our Full Disclaimer: